MediWound (NASDAQ:MDWD - Get Free Report) is set to post its quarterly earnings results before the market opens on Tuesday, November 26th. Analysts expect MediWound to post earnings of ($0.48) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.
MediWound Price Performance
NASDAQ MDWD traded up $0.16 on Tuesday, reaching $15.80. 23,821 shares of the company's stock traded hands, compared to its average volume of 90,083. The stock has a market cap of $170.48 million, a PE ratio of -7.39 and a beta of 0.83. MediWound has a 12 month low of $8.22 and a 12 month high of $24.00. The stock has a 50-day simple moving average of $17.28 and a 200 day simple moving average of $17.45.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the stock. StockNews.com raised shares of MediWound to a "sell" rating in a research note on Monday, August 5th. HC Wainwright reissued a "buy" rating and issued a $28.00 target price on shares of MediWound in a research note on Friday, October 11th.
Get Our Latest Stock Analysis on MDWD
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Further Reading
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
